David Happel
2022
In 2022, David Happel earned a total compensation of $6.5M as President and Chief Executive Officer at Sagimet Biosciences.
Compensation breakdown
| Non-Equity Incentive Plan | $211,500 |
|---|---|
| Option Awards | $6,198,479 |
| Salary | $97,917 |
| Other | $297 |
| Total | $6,508,193 |
Happel received $6.2M in option awards, accounting for 95% of the total pay in 2022.
Happel also received $211.5K in non-equity incentive plan, $97.9K in salary and $297 in other compensation.
Rankings
In 2022, David Happel's compensation ranked 451st out of 5,760 executives tracked by ExecPay. In other words, Happel earned more than 92.2% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 451 out of 5,760 | 92nd |
Division Manufacturing | 187 out of 3,136 | 94th |
Major group Chemicals And Allied Products | 49 out of 1,422 | 97th |
Industry group Drugs | 37 out of 1,323 | 97th |
Industry Pharmaceutical Preparations | 24 out of 969 | 98th |
Source: SEC filing on April 18, 2024.
Happel's colleagues
We found three more compensation records of executives who worked with David Happel at Sagimet Biosciences in 2022.